Latest News and Press Releases

– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara...

Kailera will participate in several upcoming investor conferences in November: Stifel HC Conf, Jefferies London HC Conf, TD Cowen Obesity Summit

First data from Rivus’ preclinical CMA pipeline showing potential as monotherapy and in combination with GLP-1s

Hengrui Pharma & Kailera Therapeutics Present Additional Data from Phase 3 Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531 at Obesity Week

Kailera Therapeutics appoints 30-year biopharma industry veteran Frank Clyburn, Jr to its Board of Directors

SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral...

SAN CARLOS, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today...

The November 1st episode addresses obesity misconceptions, the classification of obesity as a chronic disease, weight bias, and GLP-1s and surgery options.

Hengrui Pharma and Kailera today announced an oral presentation of HRS9531 Phase 3 data at ObesityWeek® 2025, the annual meeting of the Obesity Society.

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today announced a...